Attorney Huang, as a senior partner, has earned her law firm a new reputation in the field of M&A globally. It thanks to her representation of Gracell Biotechnology Inc.(Nasdaq.GRCL) being acquired by AstraZeneca on February 22, 2024 in the consideration of US$1.2 billion. This is the first case in history in which a Chinese biotech company has been fully acquired by a multinational pharmaceutical company. Accompanying this was her success in representing EHang Holdings Limited (Nasdaq.EH), successfully launching an At-Market Issuance (ATM) offering, issuance, and sale of up to US$100 million, reflecting her law firm’s response to China's policy of vigorously developing the economy in the low-altitude field.

Attorney Huang has led the team to expand the capital market in Chinese Mainland. A prominent case is Shanghai Shengtong Voicecomm Information Technology Co., Ltd. (Stock Code: 2495.HK) being listed on the main board of the HKSE on July 10, 2024, in which 4.36 million stocks were issued at the price of HKD152.1 per share and raised approximately HKD 664 million, in which she acted as the PRC legal counsel to the China International Capital Corporation Hong Kong Securities Limited (“CICC”), the Sole Sponsor and the Sole Overall Coordinator and 20 other underwriters.

Attorney Huang attended ORY APAC-US Conference 2024 hosted by NASDAQ and Ortoli Rosenstadt LLP to gain insights from seasoned industry experts on the U.S. capital markets and explore Asia’s vibrant business environment. To improve her skills and knowledge, she has applied and been permitted by the Washington State Bar Association to become a foreign legal counsel this year. In the future, she will continue to strive to enlarge her customer base and represent more foreign clients on their China-based issues.